TickerStat.comEloxx Pharmaceuticals annual shareholders’ equity
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Shareholders’ Equity Growth & History (ELOX)
Eloxx Pharmaceuticals's shareholders’ equity was −$11.9M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$11.9M | $12.4M | — |
| 2024 | 2024-12-31 | −$24.3M | −$1.7M | — |
| 2023 | 2023-12-31 | −$22.6M | −$11.9M | — |
| 2022 | 2022-12-31 | −$10.7M | −$33.0M | — |
| 2021 | 2021-12-31 | $22.4M | $12.2M | +118.81% |
| 2020 | 2020-12-31 | $10.2M | −$26.0M | −71.75% |
| 2019 | 2019-12-31 | $36.2M | −$6.7M | −15.61% |
| 2018 | 2018-12-31 | $42.9M | $21.6M | +100.88% |
| 2017 · Dec 31 | 2017-12-31 | $21.4M | $20.8M | +3401.80% |
| 2017 · Jun 30 | 2017-06-30 | $871,206 | −$3.7M | −80.90% |
| 2016 · Dec 31 | 2016-12-31 | $610,000 | −$33,000 | −5.13% |
| 2016 · Jun 30 | 2016-06-30 | $4.6M | −$7.7M | −62.69% |
| 2015 · Dec 31 | 2015-12-31 | $643,000 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $12.2M | −$15.3M | −55.53% |
| 2014 | 2014-06-30 | $27.5M | $23.7M | +626.08% |
| 2013 | 2013-06-30 | $3.8M | $333,039 | +9.64% |
| 2012 | 2012-06-30 | $3.5M | −$1.1M | −23.56% |
| 2011 | 2011-06-30 | $4.5M | −$3.5M | −43.40% |
| 2010 | 2010-06-30 | $8.0M | $2.3M | +40.81% |
| 2009 | 2009-06-30 | $5.7M | −$4.2M | −42.37% |
| 2008 | 2008-06-30 | $9.8M | $7.1M | +265.70% |
| 2007 | 2007-06-30 | $2.7M | −$262,427 | −8.89% |
| 2006 | 2006-06-30 | $3.0M | −$2.6M | −47.19% |
| 2005 | 2005-06-30 | $5.6M | $858,776 | +18.15% |
| 2004 | 2004-06-30 | $4.7M | $1.9M | +65.62% |
| 2003 | 2003-06-30 | $2.9M | −$1.9M | −40.31% |
| 2002 | 2002-06-30 | $4.8M | $5.0M | — |
| 2001 | 2001-06-30 | −$206,713 | −$1.7M | — |
| 2000 | 2000-06-30 | $1.5M | $606,392 | +66.48% |
| 1999 | 1999-06-30 | $912,166 | — | — |
Eloxx Pharmaceuticals quarterly shareholders’ equity
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.4M | — | — |
| Q1 2026 | 2026-03-31 | −$7.6M | — | — |
| Q4 2025 | 2025-12-31 | −$11.9M | $12.4M | — |
| Q4 2024 | 2024-12-31 | −$24.3M | −$1.7M | — |
| Q4 2023 | 2023-12-31 | −$22.6M | −$11.9M | — |
| Q3 2023 | 2023-09-30 | −$20.0M | −$15.1M | — |
| Q2 2023 | 2023-06-30 | −$18.6M | −$20.4M | — |
| Q1 2023 | 2023-03-31 | $16.3M | $4.6M | +39.42% |
| Q4 2022 | 2022-12-31 | −$10.7M | −$33.0M | — |
| Q3 2022 | 2022-09-30 | −$5.0M | −$38.0M | — |
| Q2 2022 | 2022-06-30 | $1.8M | −$38.8M | −95.54% |
| Q1 2022 | 2022-03-31 | $11.7M | $8.9M | +324.95% |
| Q4 2021 | 2021-12-31 | $22.4M | $12.2M | +118.81% |
| Q3 2021 | 2021-09-30 | $33.0M | $17.9M | +118.85% |
| Q2 2021 | 2021-06-30 | $40.6M | $20.4M | +100.30% |
| Q1 2021 | 2021-03-31 | $2.8M | −$23.5M | −89.53% |
| Q4 2020 | 2020-12-31 | $10.2M | −$26.0M | −71.75% |
| Q3 2020 | 2020-09-30 | $15.1M | −$30.1M | −66.66% |
| Q2 2020 | 2020-06-30 | $20.3M | −$34.9M | −63.26% |
| Q1 2020 | 2020-03-31 | $26.3M | −$8.2M | −23.74% |
| Q4 2019 | 2019-12-31 | $36.2M | −$6.7M | −15.61% |
| Q3 2019 | 2019-09-30 | $45.2M | −$6.2M | −12.10% |
| Q2 2019 | 2019-06-30 | $55.2M | −$4.7M | −7.83% |
| Q1 2019 | 2019-03-31 | $34.4M | $20.9M | +154.96% |
| Q4 2018 | 2018-12-31 | $42.9M | $21.6M | +100.88% |
| Q3 2018 | 2018-09-30 | $51.5M | $48.1M | +1452.34% |
| Q2 2018 | 2018-06-30 | $59.9M | $59.0M | +6777.36% |
| Q1 2018 · Mar 31 | 2018-03-31 | $13.5M | $10.9M | +422.49% |
| Q4 2017 · Dec 31 | 2017-12-31 | $21.4M | $20.8M | +3401.80% |
| Q1 2018 · Sep 30 | 2017-09-30 | $3.3M | −$311,046 | −8.58% |
| Q4 2017 · Jun 30 | 2017-06-30 | $871,206 | −$3.7M | −80.90% |
| Q1 2017 · Mar 31 | 2017-03-31 | $2.6M | −$3.1M | −54.19% |
| Q4 2016 · Dec 31 | 2016-12-31 | $610,000 | −$33,000 | −5.13% |
| Q1 2017 · Sep 30 | 2016-09-30 | $3.6M | −$8.9M | −71.01% |
| Q4 2016 · Jun 30 | 2016-06-30 | $4.6M | −$7.7M | −62.69% |
| Q1 2016 · Mar 31 | 2016-03-31 | $5.6M | −$5.6M | −49.65% |
| Q4 2015 · Dec 31 | 2015-12-31 | $643,000 | −$11.3M | −94.61% |
| Q1 2016 · Sep 30 | 2015-09-30 | $12.5M | −$9.9M | −44.25% |
| Q4 2015 · Jun 30 | 2015-06-30 | $12.2M | −$15.3M | −55.53% |
| Q3 2015 | 2015-03-31 | $11.2M | $1.4M | +14.29% |
| Q2 2015 | 2014-12-31 | $11.9M | $4.2M | +54.65% |
| Q1 2015 | 2014-09-30 | $22.4M | $20.3M | +959.31% |
| Q4 2014 | 2014-06-30 | $27.5M | $23.7M | +626.08% |
| Q3 2014 | 2014-03-31 | $9.8M | $6.5M | +196.08% |
| Q2 2014 | 2013-12-31 | $7.7M | $6.1M | +388.31% |
| Q1 2014 | 2013-09-30 | $2.1M | −$511,927 | −19.47% |
| Q4 2013 | 2013-06-30 | $3.8M | $333,039 | +9.64% |
| Q3 2013 | 2013-03-31 | $3.3M | −$1.3M | −28.00% |
| Q2 2013 | 2012-12-31 | $1.6M | −$1.3M | −44.20% |
| Q1 2013 | 2012-09-30 | $2.6M | −$1.3M | −33.15% |
| Q4 2012 | 2012-06-30 | $3.5M | −$1.1M | −23.56% |
| Q3 2012 | 2012-03-31 | $4.6M | — | — |
| Q2 2012 | 2011-12-31 | $2.8M | — | — |
| Q1 2012 | 2011-09-30 | $3.9M | — | — |
| Q4 2011 | 2011-06-30 | $4.5M | — | — |
Eloxx Pharmaceuticals shareholders’ equity trends
Over the last five fiscal years, Eloxx Pharmaceuticals's shareholders’ equity decreased from $10.2M to −$11.9M, a change of −$22.1M. The latest reported quarter, Q2 2026, shows $46.4M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...